

Special Issue

Host Targeted Therapeutics against Virus Infections

Message from the Guest Editors

The current Covid-19 pandemic and the frequent emergence and re-emergence of novel viruses highlights the urgent need for effective antivirals. The fact that every virus needs host cells to replicate sparked increasing interest in host-directed drugs that act as antivirals (host-targeted antivirals, HTA). While this approach had been heavily debated 20 years ago, the idea to target host functions for antiviral therapy was boosted due to technical developments such as cell-omics approaches and has now become widely accepted. (inhibitors of cell signaling pathways have received special attention in this respect). In this Special Issue, we want to summarize the latest findings in this field and would like to encourage research groups working on host-targeted antivirals to submit their latest findings.

Guest Editors

Prof. Dr. Oliver Planz

Prof. Dr. Stephan Ludwig

Prof. Dr. Stephan Pleschka

Deadline for manuscript submissions

closed (31 December 2022)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/73501

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/

[viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).